Fibrinogen-to-Albumin Ratio as a Predictor of Acute Respiratory Distress Syndrome in Traumatic Brain Injury (FARDS)
Fibrinogen-to-Albumin Ratio as a Predictor of Acute Respiratory Distress Syndrome in Patients With Traumatic Brain Injury: The Prospective, Observational, Multi-center FARDS Study
研究概览
详细说明
Traumatic brain injury is a major cause of morbidity and mortality worldwide and represents a significant challenge in intensive care units. In addition to the primary neurological damage, patients with moderate to severe traumatic brain injury frequently develop systemic inflammatory responses that may lead to secondary organ dysfunction. These systemic effects are mediated by activation of inflammatory cytokines, endothelial injury, and coagulation abnormalities.
Acute respiratory distress syndrome is a common and serious complication in patients with traumatic brain injury, even in the absence of direct chest trauma. Epidemiological studies indicate that acute respiratory distress syndrome develops in approximately 19-30% of severe traumatic brain injury patients, typically within the first week after injury, with a median time to onset of around 3 days.
The fibrinogen-to-albumin ratio has recently emerged as a novel biomarker reflecting both inflammatory and nutritional status. Fibrinogen is a positive acute-phase reactant that increases in response to inflammation and tissue injury, while albumin is a negative acute-phase protein that decreases during systemic inflammatory states. Previous studies have demonstrated that fibrinogen-to-albumin ratio is altered in patients with traumatic brain injury and correlates with injury severity and clinical outcomes.
Given that the same inflammatory and coagulation pathways influencing fibrinogen-to-albumin ratio in traumatic brain injury also play a central role in the development of acute respiratory distress syndrome, it is biologically plausible that early fibrinogen-to-albumin ratio measurements may predict acute respiratory distress syndrome occurrence in this patient population. However, the predictive value of fibrinogen-to-albumin ratio for acute respiratory distress syndrome in patients with traumatic brain injury has not yet been adequately investigated.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Eman M Taher, MD
- 电话号码:002 01090822808
- 邮箱:emantaher6669@gmail.com
学习地点
-
-
Gharbia Governorate
-
Tanta、Gharbia Governorate、埃及、31527
- 招聘中
- Tanta University Hospitals
-
接触:
- Eman M Taher, MD
- 电话号码:002 01090822808
- 邮箱:emantaher6669@gmail.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Patients ≥ 18 years admitted to the ICU with traumatic Brain Injury
- Admission to the ICU within 24 hours of injury.
- Patients will be expected to remain under hospital care for follow-up
- Availability of fibrinogen and albumin measurements within the first 24 hours of ICU admission.
- Informed consent will be obtained from a legally authorized representative.
Exclusion Criteria:
- Preexisting advanced chronic liver disease, nephrotic syndrome, or protein-losing enteropathy.
- Pre-existing ARDS on admission.
- Recipient of albumin, fibrinogen concentrate, or cryoprecipitate before admission sampling.
- Use of anticoagulant or fibrinolytic therapy before admission.
- Active malignancy or severe systemic infection at admission.
- Direct sever lung injury
- Pregnancy
- Refusal of consent
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Acute respiratory distress syndrome group
patients who will develop ARDS within 7 days of ICU admission, defined according to the Berlin criteria. Fibrinogen (g/L) and albumin (g/L) levels in the blood will be measured from the first routine blood sample after ICU admission. Fibrinogen-to-albumin ratio will be calculated as: FAR = Fibrinogen (g/L)/Albumin (g/L) |
Fibrinogen (g/L) and albumin (g/L) levels in the blood will be measured from the first routine blood sample after ICU admission. Fibrinogen-to-albumin ratio will be calculated as: FAR = Fibrinogen (g/L)/Albumin (g/L) |
|
Non acute respiratory distress syndrome group
patients who will not develop ARDS within 7 days of ICU admission. Fibrinogen (g/L) and albumin (g/L) levels in the blood will be measured from the first routine blood sample after ICU admission. Fibrinogen-to-albumin ratio will be calculated as: FAR = Fibrinogen (g/L)/Albumin (g/L) |
Fibrinogen (g/L) and albumin (g/L) levels in the blood will be measured from the first routine blood sample after ICU admission. Fibrinogen-to-albumin ratio will be calculated as: FAR = Fibrinogen (g/L)/Albumin (g/L) |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
The accuracy of early fibrinogen-to-albumin ratio (within 24 hours of ICU admission) to predict the development of acute respiratory distress syndrome in traumatic brain injury patients.
大体时间:up to 7 days after traumatic brain injury.
|
Fibrinogen (g/L) and albumin (g/L) levels in the blood will be measured from the first routine blood sample after ICU admission.
Fibrinogen-to-albumin ratio will be calculated as: FAR = Fibrinogen (g/L)/Albumin (g/L)
|
up to 7 days after traumatic brain injury.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of acute respiratory distress syndrome
大体时间:up to 7 days after traumatic brain injury.
|
Development of ARDS within 7 days of ICU admission, defined according to the Berlin criteria will be recorded.
|
up to 7 days after traumatic brain injury.
|
|
Severity of acute respiratory distress syndrome.
大体时间:up to 7 days after traumatic brain injury.
|
It will be evaluated by the PaO2/FiO2 ratio.
PaO2/FiO2 ratio between 200 and 300 will be considered mild ARDS.
PaO2/FiO2 ratio between 200 and 100 will be considered moderate ARDS.
PaO2/FiO2 ratio less than 100 will be considered severe ARDS.
|
up to 7 days after traumatic brain injury.
|
|
Duration of mechanical ventilation
大体时间:Up to 30 days after traumatic brain injury.
|
patients who will require mechanical ventilation for management of hypoxemia will be evaluated for the duration of mechanical ventilation.
|
Up to 30 days after traumatic brain injury.
|
|
ICU length of stay and mortality rate
大体时间:Up to 90 days after traumatic brain injury.
|
Death during ICU stay or thereafter will be recorded.
|
Up to 90 days after traumatic brain injury.
|
|
The accuracy of fibrinogen-to-albumin ratio measured at 24 hours and 48 hours after injury to predict the development of acute respiratory distress syndrome in traumatic brain injury patients.
大体时间:up to 7 days after traumatic brain injury.
|
Fibrinogen (g/L) and albumin (g/L) levels in the blood will be measured at 24 hours and 48 hours after injury.
Fibrinogen-to-albumin ratio will be calculated as: FAR = Fibrinogen (g/L)/Albumin (g/L)
|
up to 7 days after traumatic brain injury.
|
|
Predictive accuracy of delta fibrinogen-to-albumin ratio for the development of acute respiratory distress syndrome
大体时间:up to 7 days after traumatic brain injury.
|
Fibrinogen (g/L) and albumin (g/L) levels in the blood will be measured on admission and at 24 hours and 48 hours after injury. Delta fibrinogen-to-albumin ratio will be calculated as: Delta FAR (24h-0h) = FAR at 24h -FAR on admission Delta FAR (48h-0h) = FAR at 48h -FAR on admission Delta FAR (48h-24h)= FAR at 48h -FAR at 24h |
up to 7 days after traumatic brain injury.
|
|
Association of fibrinogen-to-albumin ratio with neurological outcomes at 3 months after injury
大体时间:Up to 90 days after traumatic brain injury.
|
Neurological outcomes will be assessed by the Glasgow Outcome Score (GOS).
The score is as follows: 1 = dead; 2 = vegetative state with an inability to interact with the environment; 3 = severe disability with an inability to live independently but the ability to follow commands; 4 = moderate disability with the ability to live independently but an inability to return to work or school; and 5 = good recovery with the ability to return to work or school.
A GOS of 1-3 was categorized as an unfavorable outcome, whereas a score of 4-5 was deemed a favorable outcome.
|
Up to 90 days after traumatic brain injury.
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
IPD 共享时间框架
IPD 共享访问标准
IPD 共享支持信息类型
- 研究方案
- 树液
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.